Literature DB >> 16221233

Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome.

Janet Hegarty1, M Zulf Mughal, Judith Adams, Nicholas J A Webb.   

Abstract

BACKGROUND: Children with minimal change nephrotic syndrome (MCNS) receive repeated courses of high dose oral prednisolone. No previous study has investigated the impact of this on final bone mineral density (BMD). Young adults previously reported in a large follow-up study of children with MCNS were invited to participate in a cross-sectional study. Areal BMD (aBMD) of the spine (L1-4), left femoral neck, and total left hip was measured using dual x-ray absorptiometry (DXA), and volumetric BMD (vBMD) of the distal radius was measured by pQCT. BMD results were compared with reference data provided by the manufacturers of the densitometers.
METHODS: Thirty-four (24 male) of the original cohort of 62 participated in the study. The mean (SD) final height Z score of the cohort was -0.45 (0.92) (P = 0.007) and mean BMI Z score 1.62 (1.53) (P < 0.0001).
RESULTS: There was a highly significant reduction in distal radial trabecular vBMD; the mean Z score was -0.95 (0.99) and T score -1.04 (1.01) (both P < 0.0001); however, there was no reduction in distal radial total vBMD, the mean Z score being 0.00 (0.95) and T score -0.08 (0.99), (P = 0.99 and 0.66, respectively). The aBMD of the lumbar spine and femoral neck also showed a reduction in T scores [-0.45 (1.27), P = 0.045 and -0.49 (0.86), P = 0.002, respectively], but not Z scores [-0.37 (1.28) and -0.15 (0.87), respectively, both P = NS]. Total hip aBMD was not different from the control population.
CONCLUSION: Adult survivors of childhood MCNS have a significant reduction in forearm trabecular vBMD, placing them at increased fracture risk at this site.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221233     DOI: 10.1111/j.1523-1755.2005.00690.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

1.  Obesity and other clinical endpoints in steroid-sensitive nephrotic syndrome.

Authors:  Thomas J Neuhaus; Eva-Maria Rüth; Markus Kemper
Journal:  Pediatr Nephrol       Date:  2006-12-07       Impact factor: 3.714

2.  Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.

Authors:  J Feber; I Gaboury; A Ni; N Alos; S Arora; L Bell; T Blydt-Hansen; C Clarson; G Filler; J Hay; D Hebert; B Lentle; M Matzinger; J Midgley; D Moher; M Pinsk; F Rauch; C Rodd; N Shenouda; K Siminoski; L M Ward
Journal:  Osteoporos Int       Date:  2011-04-15       Impact factor: 4.507

3.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy.

Authors:  Yoshitsugu Kaku; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Kenji Ishikura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.801

4.  Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study.

Authors:  Surabhi Choudhary; Indira Agarwal; Mandalam S Seshadri
Journal:  Pediatr Nephrol       Date:  2014-01-12       Impact factor: 3.714

Review 5.  Bone Health in Glomerular Kidney Disease.

Authors:  Dorey A Glenn; Michelle R Denburg
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

6.  Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome.

Authors:  Anne Tsampalieros; Pooja Gupta; Michelle R Denburg; Justine Shults; Babette S Zemel; Sogol Mostoufi-Moab; Rachel J Wetzsteon; Rita M Herskovitz; Krista M Whitehead; Mary B Leonard
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

7.  Vitamin D in nephrotic syndrome remission: a case-control study.

Authors:  Sushmita Banerjee; Surupa Basu; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2013-05-25       Impact factor: 3.714

8.  Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome.

Authors:  Rachel J Wetzsteon; Justine Shults; Babette S Zemel; Pooja U Gupta; Jon M Burnham; Rita M Herskovitz; Krista M Howard; Mary B Leonard
Journal:  J Bone Miner Res       Date:  2009-03       Impact factor: 6.741

9.  Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children.

Authors:  Henriette A C Kyrieleis; Marije M Löwik; Ilse Pronk; Hans R M Cruysberg; Jan A M Kremer; Wim J G Oyen; Bert L P van den Heuvel; Jack F M Wetzels; Elena N Levtchenko
Journal:  Clin J Am Soc Nephrol       Date:  2009-09-24       Impact factor: 8.237

10.  Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome.

Authors:  V Phan; T Blydt-Hansen; J Feber; N Alos; S Arora; S Atkinson; L Bell; C Clarson; R Couch; E A Cummings; G Filler; R M Grant; J Grimmer; D Hebert; B Lentle; J Ma; M Matzinger; J Midgley; M Pinsk; C Rodd; N Shenouda; R Stein; D Stephure; S Taback; K Williams; F Rauch; K Siminoski; L M Ward
Journal:  Osteoporos Int       Date:  2013-08-16       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.